Why Everyone (Almost) with HIV Needs to Be on Treatment-Reference-Cited by-同舟云学术

Why Everyone (Almost) with HIV Needs to Be on Treatment

Published:2019-09 Issue:3 Volume:33 Page:663-679
ISSN:0891-5520
Container-title:Infectious Disease Clinics of North America
language:en
Short-container-title:Infectious Disease Clinics of North America

Author:

Farel Claire E.,Dennis Ann M.

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical)

Reference68 articles.

1. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team;Hammer;N Engl J Med,1997

2. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy;Gulick;N Engl J Med,1997

3. antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel;Saag;JAMA,2018

4. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy, July 2017,2017

5. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV;Department of Health and Human Services,2018

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The changing use and program costs of HIV-related laboratory testing over 20 years in an HIV cohort;Current Opinion in HIV and AIDS;2023-07-18

2. Why we need to re‐define long‐term success for people living with HIV;HIV Medicine;2023-03

3. Temporal Trends of Clinical Characteristics and Treatments in People Living with HIV at the Initiation of Antiretroviral Therapy — Beijing Municipality, China, 2010–2020;China CDC Weekly;2023

4. Essential elements of and challenges to rapid ART implementation: a qualitative study of three programs in the United States;BMC Infectious Diseases;2022-03-31

5. Contribution of APOA5, APOC3, CETP, ABCA1 and SIK3 genetic variants to hypertriglyceridemia development in Mexican HIV-patients receiving antiretroviral therapy;Pharmacogenetics and Genomics;2021-10-22